173142-47-7

Usage

Uses

Used in Organic Synthesis:
2H-Pyrrole-2-carboxylic acid, 3,4-dihydro-5-methoxy-, methyl ester, (2S)-(9CI) is used as a synthetic intermediate for the preparation of various organic compounds. Its unique structure and functional groups make it a valuable building block in the synthesis of pharmaceuticals, agrochemicals, and other specialty chemicals.
Used in Medicinal Chemistry:
In the pharmaceutical industry, 2H-Pyrrole-2-carboxylic acid, 3,4-dihydro-5-methoxy-, methyl ester, (2S)-(9CI) is used as a key component in the development of new drugs. Its potential biological activity and specific stereochemistry allow it to be a promising candidate for the treatment of various diseases and disorders. Researchers can modify its structure to optimize its pharmacological properties, such as potency, selectivity, and bioavailability.
Used in Drug Discovery:
2H-Pyrrole-2-carboxylic acid, 3,4-dihydro-5-methoxy-, methyl ester, (2S)-(9CI) is employed in drug discovery as a starting material for the design and synthesis of novel therapeutic agents. Its unique chemical properties and potential biological activity make it an attractive scaffold for the development of new drugs with improved efficacy and safety profiles.
Used in Chemical Research:
In the field of chemical research, 2H-Pyrrole-2-carboxylic acid, 3,4-dihydro-5-methoxy-, methyl ester, (2S)-(9CI) serves as a model compound for studying the reactivity and selectivity of various chemical reactions. Its unique structure and functional groups provide insights into the underlying mechanisms of organic transformations and help researchers develop new synthetic methodologies and strategies.

Upstream product

• 77-78-1 dimethyl sulfate 
• 4931-66-2 methyl (S)-pyroglutamate 
• 420-37-1 trimethoxonium tetrafluoroborate 
• 98-79-3 L-Pyroglutamic acid 

Downstream Products

• 1190392-23-4 methyl [6(S)-4-oxo-4,6,7,8-tetrahydropyrrolo[1,2-α]]pyrimidine-6-carboxylate 
• 676148-40-6 methyl (1R,2R,5S)-4-oxo-3,8-diazabicyclo[3.2.1]octane-2-carboxylate 
• 1190393-25-9 tert-butyl(2R,5S)-2-[(R)-hydroxy(phenyl)methyl]-5-[4-({[(6S)-4-oxo-4,6,7,8-tetrahydropyrrolo[1,2-α]pyrimidin-6-yl]carbonyl}amino)benzyl]pyrrolidine-1-carboxylate 
• 1190389-15-1 (6S)-N-[4-({(2S,5R)-5-[(R)-hydroxy(phenyl)methyl]pyrrolidin-2-yl}methyl)phenyl]-4-oxo-4,6,7,8-tetrahydropyrrolo[1,2-a]pyrimidine-6-carboxamide 
• 1190392-22-3 (6S)-4-oxo-4,6,7,8-tetrahydropyrrolo[1,2-α]pyrimidine-6-carboxylic acid 
• 1190709-67-1 methyl (7S)-9-oxo-3,8-diazatetracyclo[9.2.1.0(2,10).0(4,8)]tetradeca-3,12-diene-7-carboxylate 
• 229640-43-1 phenylmethyl 3-(8-hydroxy-5-oxo-3-(benzyloxycarbonyl)-1,2,3-trihydroindolizin-6-yl)propanoate 
• 125659-61-2 (S)-6-(2-Methoxycarbonyl-ethyl)-5-oxo-1,2,3,5,6,7-hexahydro-indolizine-3,8-dicarboxylic acid 8-benzyl ester 3-methyl ester 
• 125659-62-3 (S)-6-(2-Methoxycarbonyl-ethyl)-5-oxo-1,2,3,5-tetrahydro-indolizine-3,8-dicarboxylic acid 8-benzyl ester 3-methyl ester 
• 125659-60-1 (S)-6-(2-Carboxy-ethyl)-5-oxo-1,2,3,5,6,7-hexahydro-indolizine-3,8-dicarboxylic acid 8-benzyl ester 3-methyl ester 
• 87896-52-4 (-)-A58365A 
• 125712-98-3 (S)-5-[1-Benzyloxycarbonyl-meth-(Z)-ylidene]-pyrrolidine-2-carboxylic acid methyl ester 
• 467435-24-1 (3S,6S)-6-Benzyloxycarbonylamino-5-oxo-1,2,3,5,6,7-hexahydro-indolizine-3,8-dicarboxylic acid dimethyl ester 
• 467435-25-2 (3S,6R)-6-Benzyloxycarbonylamino-5-oxo-1,2,3,5,6,7-hexahydro-indolizine-3,8-dicarboxylic acid dimethyl ester 

Relevant academic research and scientific papers

RECEPTOR INHIBITOR, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND USE THEREOF

The present invention discloses a receptor inhibitor of formula (I), a pharmaceutical composition comprising the same and the use thereof.

Pan-Tropic Entry Inhibitors

This disclsore relates to compounds according to Formula (I), salts, prodrugs and pharmaceutical formulation comprising the compound are provided herein for the treatment of CXCR4 and CCR5 related conditions. The conditions may include viral infections, a

A process for producing an intermediate agonist GRK 3

The present invention is directed to processes for preparing beta 3 agonists of Formula (I) and Formula (II) and their intermediates. The beta 3 agonists are useful in the treatment of certain disorders, including overactive bladder, urinary incontinence, and urinary urgency.

PROCESS FOR MAKING BETA 3 AGONISTS AND INTERMEDIATES

The present invention is directed to processes for preparing beta 3 agonists of Formula (I) and Formula (II) and their intermediates. The beta 3 agonists are useful in the treatment of certain disorders, including overactive bladder, urinary incontinence, and urinary urgency.

Synthesis of an azabicycloalkane amino acid scaffold as potential rigid dipeptide mimetic

Short syntheses are presented of the pseudo-dipeptide (3S,6S)-6-[(benzyloxy)carbonyl]amino-5-oxo-1,2,3,5,6,7-hexahydro-3- indolizinecarboxylic acid (1a) and of its (3S,6R) diastereoisomer (1b). The key step involves adding vinylogous β-enaminoester derived from pyroglutamic acid on an acrylate derivative. The 6,5-fused bicyclic lactam obtained may be viewed as a conformationally restricted Ala-Pro mimetic.